Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells.
Changes in glomerular eicosanoid production have been implicated in the development of diabetes-induced glomerular hyperfiltration and glomerular mesangial cells (GMC) are major eicosanoid-producing cells within the glomerulus. However, the mechanism for the effect of diabetes mellitus on glomerular mesangial eicosanoid production is unknown. The present study therefore examined whether elevated glucose concentrations activate protein kinase C (PKC) in GMC and whether this PKC activation mediates an effect of elevated glucose concentrations to increase the release of arachidonic acid and eicosanoid production by GMC. The percentage of [3H]arachidonic acid release per 30 min by preloaded GMC monolayers was significantly increased after 3-h exposure to high glucose (20 mM) medium (177% vs control medium) and this increase was sustained after 24-h exposure to high glucose concentrations. 3-h and 24-h exposure to high glucose medium also increased PGE2, 6-keto-PGF1 alpha, and thromboxane (TXB2) production by GMC. High glucose medium (20 mM) increased PKC activity in GMC at 3 and 24 h (168% vs control). In contrast, osmotic control media containing either L-glucose or mannitol did not increase arachidonic acid release, eicosanoid production, or PKC activity in GMC. Inhibiting glucose-induced PKC activation with either H-7 (50 microM) or staurosporine (1 microM) prevented glucose-induced increases in arachidonic acid release and eicosanoid production by GMC. These data demonstrate that elevated extracellular glucose concentrations directly increase the release of endogenous arachidonic acid and eicosanoids by GMC via mechanisms dependent on glucose-induced PKC activation.
Williams
B
B
Department of Medicine, University of Colorado Health Sciences Center, Denver 80262.
Schrier
R W
RW
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000470:Alkaloids / Q000494:pharmacology; D000595:Amino Acid Sequence; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism*; D002478:Cells, Cultured; D003470:Culture Media; D015777:Eicosanoids / Q000378:metabolism*; D005920:Glomerular Mesangium / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology; D007700:Kinetics; D008353:Mannitol / Q000494:pharmacology; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000378:metabolism; D010741:Phospholipases A / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011453:Prostaglandins / Q000096:biosynthesis*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D019311:Staurosporine; D013379:Substrate Specificity; D013929:Thromboxane B2 / Q000378:metabolism; D014316:Tritium
D000470:Alkaloids; D003470:Culture Media; D015777:Eicosanoids; D007546:Isoquinolines; D009842:Oligopeptides; D010879:Piperazines; D011453:Prostaglandins; D014316:Tritium; D016718:Arachidonic Acid; D008353:Mannitol; D013929:Thromboxane B2; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D011493:Protein Kinase C; D010741:Phospholipases A; D019311:Staurosporine; D005947:Glucose